Roche snags first-in-class FDA nod for lymphoma drug Polivy

The FDA on Monday approved Roche’s Polivy, formerly known as polatuzumab, in combo with Rituxan and the chemotherapy bendamustine to treat diffuse large B-cell lymphoma patients who've failed on at least two prior treatments. The accelerated approval could be contingent on results from a confirmatory trial.